首页> 外文OA文献 >Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice
【2h】

Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice

机译:A2A和A2B腺苷受体在使用A2B和A2A / 2B双敲除小鼠的KATP通道中对冠脉血流反应的贡献

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adenosine plays a role in physiological and pathological conditions, and A2 adenosine receptor (AR) expression is modified in many cardiovascular disorders. In this study, we elucidated the role of the A2BAR and its relationship to the A2AAR in coronary flow (CF) changes using A2B single-knockout (KO) and A2A/2B double-KO (DKO) mice in a Langendorff setup. We used two approaches: 1) selective and nonselective AR agonists and antagonists and 2) A2AKO and A2BKO and A2A/2BDKO mice. BAY 60-6583 (a selective A2B agonist) had no effect on CF in A2BKO mice, whereas it significantly increased CF in wild-type (WT) mice (maximum of 23.3 ± 9 ml·min-1·g-1). 5'-N-ethylcarboxamido adenosine (NECA; a nonselective AR agonist) increased CF in A2BKO mice (maximum of 34.6 ± 4.7 ml·min-1·g-1) to a significantly higher degree compared with WT mice (maximum of 23.1 ± 2.1 ml·min-1·g-1). Also, CGS-21680 (a selective A2A agonist) increased CF in A2BKO mice (maximum of 29 ± 1.9 ml·min-1·g-1) to a significantly higher degree compared with WT mice (maximum of 25.1 ± 2.3 ml·min-1·g-1). SCH-58261 (an A2A-selective antagonist) inhibited the NECA-induced increase in CF to a significantly higher degree in A2BKO mice (19.3 ± 1.6 vs. 0.5 ± 0.4 ml·min-1·g-1) compared with WT mice (19 ± 3.5 vs. 3.6 ± 0.5 ml·min-1·g-1). NECA did not induce any increase in CF in A2A/2BDKO mice, whereas a significant increase was observed in WT mice (maximum of 23.1 ± 2.1 ml·min-1·g-1). Furthermore, the mitochondrial ATP-sensitive K(KATP) channel blocker 5-hydroxydecanoate had no effect on the NECAinduced increase in CF in WT mice, whereas the NECA-induced increase in CF in WT (17.6 ± 2 ml·min-1·g-1), A2AKO (12.5 ± 2.3 ml·min-1·g-1), and A2BKO (16.2 ± 0.8 ml·min-1·g-1) mice was significantly blunted by the KATP channel blocker glibenclamide (to 0.7 ± 0.7, 2.3 ± 1.1, and 0.9 ± 0.4 ml·min-1·g-1, respectively). Also, the CGS-21680-induced (22 ± 2.3 ml·min-1·g-1) and BAY 60-6583-induced (16.4 ± 1.60 ml·min-1·g-1) increase in CF in WT mice was significantly blunted by glibenclamide (to 1.2 ± 0.4 and 1.8 ± 1.2 ml·min-1·g-1, respectively). In conclusion, this is the first evidence supporting the compensatory upregulation of A2AARs in A2BKO mice and demonstrates that both A2AARs and A2BARs induce CF changes through KATP channels. These results identify AR-mediated CF responses that may lead to better therapeutic approaches for the treatment of cardiovascular disorders. © 2011 the American Physiological Society.
机译:腺苷在生理和病理状况中起作用,并且在许多心血管疾病中A2腺苷受体(AR)的表达被修饰。在这项研究中,我们使用Langendorff装置中的A2B单敲除(KO)和A2A / 2B double-KO(DKO)小鼠阐明了A2BAR的作用及其与A2AAR在冠脉流量(CF)变化中的关系。我们使用两种方法:1)选择性和非选择性AR激动剂和拮抗剂,以及2)A2AKO和A2BKO和A2A / 2BDKO小鼠。 BAY 60-6583(一种选择性的A2B激动剂)对A2BKO小鼠的CF无影响,而在野生型(WT)小鼠中CF显着增加(最大23.3±9 ml·min-1·g-1)。 5'-N-乙基羧酰胺基腺苷(NECA;非选择性AR激动剂)与WT小鼠(最大23.1±)相比,使A2BKO小鼠的CF增加(最大34.6±4.7 ml·min-1·g-1)。 2.1ml·min-1·g-1)。另外,CGS-21680(一种选择性的A2A激动剂)与WT小鼠(最大25.1±2.3 ml·min)相比,A2BKO小鼠(最大29±1.9 ml·min-1·g-1)的CF升高程度更高。 -1·g-1)。与WT小鼠相比,SCH-58261(一种A2A选择性拮抗剂)在A2BKO小鼠中抑制了NECA诱导的CF升高(19.3±1.6 vs. 0.5±0.4 ml·min-1·g-1)的程度明显更高( 19±3.5 vs. 3.6±0.5 ml·min-1·g-1)。 NECA不会在A2A / 2BDKO小鼠中诱导CF的任何增加,而在WT小鼠中观察到了显着的增加(最大23.1±2.1 ml·min-1·g-1)。此外,线粒体ATP敏感性K(KATP)通道阻滞剂5-羟基癸酸酯对WTCA小鼠的NECA诱导的CF增加没有影响,而NECA诱导的WT的CF增加(17.6±2 ml·min-1·g -1),KATP通道阻滞剂格列本脲使A2AKO(12.5±2.3 ml·min-1·g-1)和A2BKO(16.2±0.8 ml·min-1·g-1)小鼠明显变钝(至0.7±分别为0.7、2.3±1.1和0.9±0.4 ml·min-1·g-1。此外,WT小鼠的CF升高是CGS-21680诱导的(22±2.3 ml·min-1·g-1)和BAY 60-6583诱导的(16.4±1.60 ml·min-1·g-1)增加。格列本脲明显钝化(分别为1.2±0.4和1.8±1.2 ml·min-1·g-1)。总之,这是支持A2BKO小鼠中A2AARs补偿性上调的第一个证据,并证明A2AARs和A2BARs均通过KATP通道诱导CF变化。这些结果确定了AR介导的CF反应,可导致更好的心血管疾病治疗方法。 ©2011美国生理学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号